Skip to main content
Robert Bhisitkul, MD, Ophthalmology, San Francisco, CA

RobertB.BhisitkulMD

Ophthalmology San Francisco, CA

Professor, Ophthalmology, UCSF School of Medicine

Dr. Bhisitkul is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Bhisitkul's full profile

Already have an account?

  • Office

    400 Parnassus Ave
    San Francisco, CA 94143
    Phone+1 415-353-2402
    Fax+1 415-353-2713

Education & Training

  • Massachusetts Eye and Ear Infirmary/Harvard Medical School
    Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 1993 - 1996
  • New York Medical College at St Vincent's Hospital and Medical Center of New York
    New York Medical College at St Vincent's Hospital and Medical Center of New YorkInternship, Transitional Year, 1992 - 1993
  • Stanford University School of Medicine
    Stanford University School of MedicineClass of 1992

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1998 - 2026
  • MA State Medical License
    MA State Medical License 1996 - 1999
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
    Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular EdemaMarch 23rd, 2023
  • UNITY Biotechnology’s Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the Eye
    UNITY Biotechnology’s Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the EyeOctober 11th, 2022
  • UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye Disease
    UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye DiseaseNovember 9th, 2021
  • Join now to see all

Professional Memberships